Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En tidlig gennemførlighedsevaluering af en ny 3rdMolarTooth Bud-ablationsprocedure (Zero3)

22. september 2026 opdateret af: TriAgenics Inc

The goal of this single-arm prospective, non-randomized study is to demonstrate microwave ablation and agenesis of 3rd molar tooth buds using the Zero3 System in participants that have 3rd molar tooth bud(s) without the formation of enamel (calcification). The main question it aims to answer is the safety of the ablation procedure. Also effectiveness of 3rd molar tooth bud ablation and resulting agenesis will be assessed.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

TriAgenics has developed a highly controllable, safe means of suppressing development of third molar tooth buds. Its unique Zero3 micro-ablation handpiece delivers microwave energy that results in spherical zones of ablation. The Zero3 treatment works by gently warming the wisdom tooth bud from the center outwards in a controlled fashion to ablate the tooth bud tissue and prevent it from being able to form a tooth.

The image-guided Zero3 procedure employs a simple puncture of the tooth bud followed by a 25-95 second ablation cycle. Because of the high level of control enabled by the image-guided ablation, the ablation zone matches the size of the tooth bud with no unplanned cell damage outside the bony crypt of the tooth bud. This results in a procedure with a fully enclosed surgical field with virtually no surgical trauma.

Microwave ablation of tooth buds for eligible children will be performed on day 0 and adverse events and progression of tooth bud effects will be monitored over time after the procedure. Participants will return to the dentist at 1, 7, 30, and 90 days post-procedure for assessment of the treatment site. Participants will exit the study at 90 days unless further monitoring is warranted. If further monitoring does occur, it will only be for an additional 90 days.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

35

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Panamá Province
      • Panama City, Panamá Province, Panama
        • Universidad Interamericana de Panamá
        • Kontakt:
        • Kontakt:
          • VIRGILIO B. CASTILLERO D, DDS
          • Telefonnummer: +50766799195
          • E-mail: vicas21@yahoo.com

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

8 år til 12 år (Barn)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Participant has radiographic evidence of at least one mandibular 3rd molar tooth bud between 4 and 8 mm in largest diameter, which typically presents in children between 8 and 12 years of age, and
  2. Participant is free from any clinically significant health or behavioral problems that the investigator determines will be inappropriate for inclusion in the Study, and
  3. Participant has normal facial and oral anatomy and is free from any abnormality or condition which may impact the performance of the procedure, and
  4. Participant's parent or legal guardian is willing and able to sign the approved Informed Consent Form ("ICF") and the Participant will agree with the Participant Assent Form and the Participant is willing and able to provide age-appropriate assent and comply with required study procedures and follow-up.

Exclusion Criteria:

  1. Participant where use of local anesthetic is contraindicated, or
  2. Participant has any behavioral or medical condition which, in the opinion of the Investigator, would prevent adequate performance of the procedure or affect the health and/or safety of the Participant, or
  3. Participants with orthodontics (traditional braces or clear aligners), or
  4. Participant is immunocompromised, has a history of or potential for bone tissue defects, or has any known sensitivities to anesthetic agents, or Exclusion Post Radiological Exam (by Sponsor) from review of the LL8/#17 and LR8/#32 tooth buds
  5. Adjacent 2nd molar has incomplete enamel formation, or
  6. Tooth bud has enamel formation (calcification) visible on radiographs, or
  7. Tooth bud has a diameter of less than 4 mm or greater than 8 mm, or
  8. Tooth bud has less than 3 mm separation from the inferior alveolar nerve canal.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Enhedens gennemførlighed
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Zero3 Procedure

Induce third molar tooth bud agenesis

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of puncture site wound healing
Tidsramme: 1, 7, 30, and 90 days after the procedure

The site of the puncture of the electrode will be visually evaluated by the treating dentist. Success is defined as greater than 90% healing of the puncture site by 90 days after the procedure by visual evaluation by the investigator.

1, 7, 30, and 90 days after the procedure
Incidence of Adverse Events
Tidsramme: 1, 7, 30, and 90 days after the procedure.

Serious adverse events related to the procedure. Reviewed by the Medical Monitor and classify each as serious or not serious.

1, 7, 30, and 90 days after the procedure.
Pain during and after the procedure
Tidsramme: Before being released on the day of the procedure and then 1, 7, 30, and 90 days after the procedure

The participant will be asked to rank the pain using the Faces Pain Scale-Revised after and then at each monitoring visit. Mean pain scale will be determined for all participants.

Before being released on the day of the procedure and then 1, 7, 30, and 90 days after the procedure

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Radiographic evidence of treated third molar formation after treatment
Tidsramme: 30 and 90 days after the treatment

Periodical x-ray images will be taken at intervals after the treatment to document any third molar mineralization tooth structure formation after the treatment. Presence of tooth structure will be assessed by the Sponsor, the investigator, and the Medical Monitor.

30 and 90 days after the treatment
Diameter of bony crypts after treatment
Tidsramme: 30 and 90 days after the treatment

The maximum diameter of the boney crypt will be compared on per-op and post-op x-rays. Reduction in diameter of boney crypts will be measured and calibrated using the first molar anterior/posterior size as a reference.

30 and 90 days after the treatment

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Leigh Colby, DDS, TriAgenics Inc

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. september 2026

Primær færdiggørelse (Anslået)

30. juni 2027

Studieafslutning (Anslået)

30. juni 2027

Datoer for studieregistrering

Først indsendt

6. maj 2022

Først indsendt, der opfyldte QC-kriterier

10. maj 2022

Først opslået (Faktiske)

16. maj 2022

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

25. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • TP-025

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner